Skip to main content
. 2021 Summer;20(3):351–367. doi: 10.22037/ijpr.2020.114347.14806

Tabla 3.

Molinspiration bioactivity calculations of the synthesized hybrids 9-12

Compounds Bioactivity score a
GPCR ligand b Ion channel modulator Kinase inhibitor N uclear receptor ligand Protease inhibitor Enzyme inhibitor
9a -0.19 -0.25 -0.67 -0.46 0.04 -0.06
9b -0.20 -0.26 -0.66 -0.41 0.04 -0.10
9c -0.12 -0.24 -0.59 -0.35 0.12 -0.04
10a 0.03 -0.11 -0.20 -0.34 0.12 -0.00
10b -0.02 -0.12 -0.23 -0.34 0.10 -0.04
10c 0.02 -0.12 -0.22 -0.32 0.12 0.01
11a -0.03 -0.24 -0.55 -0.37 0.16 -0.06
11b -0.08 -0.25 -0.56 -0.39 0.11 -0.10
11c -0.04 -0.24 -0.54 -0.36 0.14 -0.05
12a 0.02 -0.20 -0.68 -0.38 0.29 -0.05
12b -0.03 -0.20 -0.69 -0.39 0.25 -0.08
12c 0.01 -0.19 -0.65 -0.36 0.27 -0.03

aIf bioactivity score > 0 (active), −5.0 – 0.0 (moderately active), < −5.0 (inactive): based on activity scores for the six most important FDA-approved drugs bGPCR = G-protein coupled receptor.